A Parallel-Group Comparison of Two Doses Of Multihance (0.10 mmol/Kg and 0.05 mmol/Kg) When Used For Magnetic Resonance Imaging (MRI) of The Central Nervous System (CNS)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Gadobenic acid (Primary)
- Indications CNS disorders
- Focus Diagnostic use
- Sponsors Bracco Diagnostics
- 07 Feb 2018 Planned End Date changed from 1 Dec 2017 to 30 Apr 2018.
- 07 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.